Preclinical Neuroprotection: Mechanisms of MAO-B Inhibitors and Their Metabolites

FACULTY
Stephen M. Setter, PharmD, DVM, CGP, CDE, FASCP
Associate Professor of Pharmacotherapy
College of Pharmacy
Washington State University/Elder Services
Spokane, Washington

Lindy D. Wood, PharmD
Specialty Resident in Geriatrics
College of Pharmacy
Washington State University/Elder Services
Spokane, Washington

Dr. Setter hereby states that he has the following financial relationship to products or devices with a commercial interest related to the content of this activity: member of the speakers bureau for Teva Neuroscience, Inc.

Dr. Wood hereby states that she does not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

The following PIM planners and managers, Jan Hixon, RN, BSN, MA, Trace Hutchison, PharmD, Julia Kimball, RN, BSN, Samantha Mattiucci, PharmD and Jan Schultz, RN, MSN, CCMEP hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

ACCREDITATION STATEMENT
Pharmacy
Postgraduate Healthcare Education, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
UAN: 0430-0000-10-010-H01-P; 0430-0000-10-010-H01-T
Credits: 2.0 hours (0.20 ceu)

TYPE OF ACTIVITY: Knowledge

Media: Internet

Fee Information:
There is no fee for this educational activity.

Estimated time to complete activity:
120 minutes.

ACCME Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Postgraduate Institute for medicine (PIM) and Postgraduate Healthcare Education, LLC. PIM is accredited by the ACCME to provide continuing medical education for physicians.
 
Published: April 1, 2010
Expires: April 30, 2011

Credit Designation
Postgraduate Institute for Medicine designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credits^™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Exam processing inquiries and other inquiries and booklet orders to:
CE Customer Service Manager (800) 825-4696

PROCEDURE
Please complete the posttest questions and activity evaluation online at: www.powerpak.com (a username and password are required to access your account). Upon passing the exam with a score of 70% or better, you can print out your statement of credit immediately. You can also view your test history at any time and print out duplicate statements from the Web site.

TARGET AUDIENCE
This accredited activity is targeted to physicians, physician assistants, nurse practitioners, pharmacists, and pharmacy technicians.

STATEMENT OF NEED/PROGRAM OVERVIEW
This program has been developed to provide participants with an update about the preclinical features and progression of Parkinson’s disease, the potential neuroprotective properties of monoamine oxidase B (MAO-B) inhibitors, and some disease modification trials assessing neuroprotection.

EDUCATIONAL OBJECTIVES
After completing this activity, participants should be able to:

1. Discuss the importance of the preclinical nonmotor features of Parkinson’s disease, the importance of early diagnosis, and the need to treat early;*
2. Compare monoamine oxidase B (MAO-B) inhibitors and improve awareness of the selectivity of MAO-B inhibitors;*
3. Describe purported mechanisms of neuroprotection with MAO-B inhibitors and their metabolites; and
4. Compare outcome measures and trial designs in regard to disease modification trials.

*Also applies to pharmacy technicians

DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by PIM for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. PIM is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Postgraduate Institute for Medicine (PIM), Postgraduate Healthcare Education, LLC, (PHE) and Teva Neuroscience, Inc., do not recommend the use of any agent outside of the labeled indications.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.